Through the advent of UNC’s Science & Technology Innovation Center (STIC), students and faculty now study, conduct research, and work alongside the STIC start-up companies’ engineers, administrators, marketing, sales, quality, and regulatory personnel.
Presently, STIC is incubating the start up of three biomedical engineering device companies: Osseon Therapeutics, Inc.; Sapheon, Inc., and Tisugen Therapeutics, LLC.
Osseon Therapeutics, Inc. aims to be the principal provider of alternative minimally invasive treatments for bone diseases. Osseon’s initial medical device products are designed to provide vertebroplasty and kyphoplasty (medical procedures to help persons suffering with osteoporosis and osteo-traumatic injuries of the spine) market with cost-competitive and clinically superior devices to those presently employed.
Sapheon, Inc. has developed patent-pending devices that will greatly improve procedures for the treatment of venous reflux disease. Sapheon’s devices and surgical methods will increase procedure effectiveness, decrease cost, reduce pain, and can be performed in an outpatient setting quickly with short patient recovery period.
Tisugen Therapeutics, LLC’s main mission is to develop effective methods and devices for significantly reducing or alleviating pain, as well as decreasing the cost of treatment, for persons suffering with moderate to severe osteoarthritis (OA) of the knee. Tisugen has developed and patented an OA knee treatment that obviates the need for surgical treatments for a vast number of individuals with moderate to severe knee OA.